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Abstract: 
Chlamydiae cause a wide range of diseases in human and animal hosts. Chlamydia pneumoniae 
and Chlamydia trachomatis are important human pathogens with worldwide distribution that 
produce significant morbidity. Acute infections with C. pneumoniae cause respiratory tract 
infections, while chronic infection has been linked to chronic bronchitis, asthma and 
atherosclerosis. Ocular serovars of C. trachomatis induce trachoma, the leading cause of 
blindness worldwide. C. trachomatis is the most common bacterial cause of sexually-transmitted 
diseases (STDs) worldwide. Acute infections with genital serovars of C. trachomatis remain 
clinically silent in most women but can progress to upper genital tract infection leading to pelvic 
inflammatory disease (PID), infertility and ectopic pregnancy. Chlamydia-induced, reactive 
arthritis can develop as a late-term condition after genital C. trachomatis or respiratory C. 
pneumoniae infection. In this review we address recent information on pathogenesis, immune 
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 2 
response, diagnosis and treatment of chronic diseases induced by C. trachomatis and C. 
pneumoniae. 
 
Introduction  
The chlamydiae, Gram-negative, obligate intracellular bacteria, cause a broad range of diseases, 
affecting a wide range of economically important non-human animals and humans. All 
chlamydiae share a biphasic developmental cycle. The primary developmental forms of 
chlamydiae are elementary bodies (EB) and reticulate bodies (RB). EB, the extracellular form of 
the bacteria, are small (0.2 um) and infectious, targeting host mucosal epithelial cells. After 
attachment and entry into the host cell, EB develop within a membrane bound endocytic vacuole 
called an inclusion. Inside the inclusion, EB differentiate into larger (0.8 um), metabolically 
active but noninfectious RB, which undergo multiple rounds of division. RB re-differentiate into 
infectious EB, and mature EB complete the developmental cycle, exiting the host cell via lysis or 
extrusion of the inclusion [1]. Stressors of developing chlamydiae, including the host immune 
response, nutrient deprivation, antibiotics exposure or co-infection with viruses or parasites, can 
result in a form called aberrant bodies (AB). AB develop when RB replicative division and 
maturation of RB to EB is interrupted, resulting in abnormally large chlamydiae. This divergence 
from the typical developmental cycle constitutes a viable but noninfectious form of chlamydiae, 
and is termed persistence or the chlamydial stress response, a reversible condition that can 
eventually allow continued production of infectious EB [1–2, 3•, 4].    
In humans, chlamydiae usually cause eye, urogenital or respiratory infections.  Chlamydia 
trachomatis is the most common bacterial sexually transmitted disease (STD) and the leading 
cause of infectious blindness worldwide. C. pneumoniae, an agent of respiratory infection, is 
nearly ubiquitous in humans, with seropositivity rates of 70-80% in older populations, suggesting 
most people experience infection during their lifetime [5]. C. psittaci, a common pathogen of 
birds, has the best known zoonotic potential of the human pathogenic chlamydiae and causes 
relatively rare respiratory infections associated with severe clinical manifestations, while several 
other animal pathogenic chlamydial species, including C. abortus, C. felis, and C. suis, are 
known, or suspected, to cause infrequent human infections with various clinical presentations 
[6,7]. Chronic chlamydial infections in animals, particularly ruminants and pigs, are sub-clinical 
and ubiquitous in nature [8,9]. Although their pathogenic significance is a debateable, recent data 
suggest clinical impact when these infections coincide with various epidemiological risk factors.  
Chronic chlamydial human disease has well-recognized medical significance, encompassing the 
most detrimental outcomes of chlamydial disease, and is the topic of this review. 
By definition, chronic diseases are long lasting conditions which can be controlled but not cured. 
The term chronic, however, is usually applied when the disease lasts more than three months, 
regardless of the eventual outcome [10]. Chronic disease is the leading cause of death and 
disability in the United States [11]. In Europe, chronic conditions account for 86% of all deaths 
and 77% of the disease burden [12]. Chronic diseases also significantly increase health care costs 
related to long-term medical care. Exposure to infectious agents has been implicated as a risk 
factor for development of chronic diseases, and strong association has been recently shown for 
five pathogens: human immunodeficiency virus (HIV), hepatitis C virus, Helicobacter pylori, 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 3 
and Chlamydia (C.) pneumoniae [12].  Association of chlamydiae other than C. pneumoniae with 
chronic disease is also well supported.  
In this article, we review the role of chlamydiae in chronic disease conditions including 
atherosclerosis, trachoma, urogenital infections and arthritis. Chlamydiae have been implicated 
in neurological chronic diseases, such as multiple sclerosis and Alzheimer’s disease, and in 
neurobehavioral diseases such as autism and schizophrenia [13], but because supporting 
evidence is contradictory, these diseases will not be discussed here. Additionally, chlamydial 
infection has been associated with cervical, ovarian, and prostate cancers [14,15], but again, 
evidence supporting the association is inconsistent and this topic will not be discussed at length. 
Because of length limitations, we focus on the intensively investigated chlamydial species C. 
trachomatis and C. pneumoniae in humans. We will: i) address the clinical significance and 
public health impact of chronic chlamydial diseases; ii) summarize pathogenesis emphasizing 
host-pathogen interaction including host immune response and bacterial factors associated with 
disease; iii) discuss diagnostic methods and therapeutics in the light of chronicity and; iv) 
indicate future research directions.  
 
Chlamydia trachomatis: trachoma and blindness 
Trachoma, caused by ocular strains of C. trachomatis, causes visual impairment of about 2.2 
million people, of whom 1.2 million are irreversibly blind [16]. Globally, it is estimated that 
more than 50 countries are endemic for blinding trachoma, mainly in Africa and the Middle East, 
but also in Asia, Latin America and the western Pacific [17]. However, estimates for global 
trachoma vary considerably due to limited reliable survey data from endemic regions [18]. 
Trachoma is associated with poor hygiene status and extreme poverty [17]. It is a family based 
disease clustering in certain communities, and specific households within these communities. 
The disease is spread by direct contact with ocular and nasal discharges, contact with fomites, or 
contact with eye-seeking flies, vectors for the disease.  Trachoma is thus a disease specific to 
poor rural regions in less developed countries and is part of the Neglected Tropical Diseases 
Program [16]. 
Ocular serovars (A, B, Ba, and C) of C. trachomatis have highly specific tropism for mucosal 
epithelia of ocular conjunctiva. Infection of the conjunctival epithelium leads to conjunctivitis 
and triggers an immune response characterized by a marked inflammatory cell infiltrate and 
release of pro-inflammatory cytokines in the conjunctiva [18,19•]. One episode of infection 
results in self-limiting chlamydial conjunctivitis, an acute phase referred to as active trachoma. 
The World Health Organization (WHO) estimates 40 million people worldwide have active 
trachoma [16]. Infection is usually acquired in infancy in hyperendemic regions and active 
trachoma is mostly seen in children, progressing to eyelid scarring and blindness in adulthood. 
Active trachoma is frequently found in the absence of detectable C. trachomatis infection and is 
clinically represented by papillary and/or follicular inflammation of the tarsal conjunctiva. 
Repeated and/or persistent infections trigger sustained inflammation and scarring of the upper 
tarsal conjunctiva. Scarring and fibrosis, in turn, distort the upper eyelid and facilitate inturning 
of the eyelid (entropion) and eyelashes (trichiasis) causing irritation of the corneal surface and 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 4 
irreversible blindness. The scarring and trichiasis that leads to corneal opacity and sustained 
pathological tissue reaction to inflammation constitutes the second phase of trachoma.  
The WHO Simplified Trachoma Grading System divides active trachoma into two often 
coexisting phenotypes: Trachoma Inflammation Follicular (TF) and Trachoma Inflammation 
Intense (TI) [18]. Chronicity and progression to inflammatory eye lesions are classified in the 
WHO system as Trachomatous Scarring (TS), reflected by tarsal conjunctiva scarring, and 
Trachomatous Trichiasis (TT) including at least one eyelash rubbing on the eyeball. The most 
severe disease sequela is blinding Corneal Opacity (CO) [18].  The immune response to C. 
trachomatis provides only partial protection, is serovar-specific and does not prevent reinfection 
[19•]. Tissue damage and scarring result from chronic, pathological immune reactions. Related 
immunity and immunopathogenesis has been studied in mouse and guinea pig animal models, 
and data more comparable to human trachoma have been obtained from non-human primate 
studies. Scarring complications result from complex interactions between infectious burden, 
local immune response and host genetic polymorphisms related to immune function.  
Repeated reinfections are implicated in development of chronic scarring disease [19•]. The role 
of persistent, non-replicating chlamydial forms in ocular infections is unclear and controversial 
within the chlamydial field [20]. Tissue damage and fibrosis in Chlamydia-related diseases are 
thought to result from cell mediated immunity responses against chlamydial antigens, either by 
delayed type hypersensitivity or molecular mimicry [21].  In trachoma, infected conjunctival 
epithelial cells secrete pro-inflammatory cytokines, chemokines, and growth factors, which 
recruit inflammatory immune cells. Inflammatory cells such as neutrophils and macrophages 
disrupt normal tissue architecture by releasing mediators such as toxic reactive oxygen and 
nitrogen species and matrix metalloproteinases (MMP). MMP9 can degrade collagen IV leading 
to basement membrane disruption, and pro-fibrinogenic factors are thought to stimulate activated 
fibroblasts to produce collagen, causing scarring.  
Key factors influencing trachoma development and progression are the presence of different 
strains circulating within communities, pathogen burden of infected individuals and 
polymorphisms in specific host genes. Host polymorphism in immune response genes is 
hypothesized to play a significant role in trachoma disease progression [22•]. Single nucleotide 
polymorphisms in the Interleukin-10 (IL-10) gene, the tumor necrosis factor (TNF) locus and 
MMP-9 have been implicated in trachoma pathogenesis [22•]. Recently, specific combinations of 
polymorphisms in Human Leucocyte Antigen C (HLA-C) ligands and their inhibitory Killer-cell 
Immunoglobulin-like Receptors (KIRs) were associated with increased risk of conjunctival 
scarring in trachoma patients [23]. Besides host polymorphisms, genetic variation of C. 
trachomatis impacts disease severity and tissue tropism [22•]. Major outer membrane protein 
(MOMP) serovar predicts chlamydial disease biovars (A-C: endemic trachoma) but does not 
reflect disease severity differences. Polymorphisms in chlamydial genes such as Tarp, Inc, 
CT229, pmp and cytotoxin appear to influence disease severity and tissue tropism, however, 
clear links and mechanisms are unknown. Distinction between ocular and genital strains can also 
be made based on mutations in the tryptophan synthase genes [24]. 
Documented C. trachomatis infection correlates poorly with clinical sequelae [25], complicating 
diagnosis of trachoma. Nucleic acid amplification tests (NAATs) are sensitive and specific, but 
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 5 
results do not correlate with clinical grading. In vivo confocal microscopy has been recently used 
to visualize progression of inflammatory and scarring changes [26]. Commercial NAATs do not 
detect Chlamydiaceae species other than C. trachomatis. Single and mixed infections with C. 
trachomatis, C. psittaci, C. suis, C. pecorum and C. pneumoniae were detected in conjunctival 
samples of trachoma patients by ArrayTube microarray [27]. This finding and the potential 
zoonotic origin of these Chlamydiaceae species other than C. trachomatis might have 
implications for immunopathology and disease outcome in trachoma patients, therapeutic 
treatment and future vaccine development. 
The WHO launched an initiative with the ambitious goal of eliminating blinding trachoma 
globally by 2020. The SAFE strategy includes: surgery for trichiasis, antibiotics for active 
trachoma, facial cleanliness, and environmental improvement [16]. Current WHO 
recommendations constitute mass treatment with a single dose of azithromycin. The risk of 
adverse events and possible antibiotic resistance development due to azithromycin treatment 
merit consideration, but ancillary benefits such as reduced infectious disease and decreased 
childhood mortality outweigh these concerns [25]. Success of trichiasis surgery is impeded by 
high recurrence rate (5-40%), poor surgical technique, limited accessibility to surgery and lack of 
acceptance of surgery among the local population [28]. Limiting exchange of ocular secretions 
can be achieved by facial cleanliness and improvement of hygiene conditions (environmental 
improvement) to decrease transmission [28].  
 
 
Chlamydia trachomatis: genital infections  
C. trachomatis is the most common bacterial cause of STD worldwide. In the United States, 1.4 
million chlamydial infections were reported by the Centers for Disease Control and Prevention 
(CDC) in 2011 [29] and the WHO estimates that more than 90 million persons are infected 
worldwide [30]. The greatest burden is in sexually active women aged 14 to 19 years, with 
prevalence of approximately 6.8% in the United States [31]. The major age groups for 
chlamydial STD are women aged 18 to 20 and men aged 20 to 24 years. Moreover, many 
patients are asymptomatic (70-90% of women, 30-50% of men), thus most cases likely remain 
undiagnosed/unreported [29]. Risk factors include young adulthood, multiple sex partners, 
intermittent condom use, cervical ectopy, history of other STD such as HIV, low education 
status, low socioeconomic class, and anal receptive intercourse [29]. High risk types of human 
papillomavirus (HPV) are principle causative agents in cervical cancer, but C. trachomatis 
infection is a co-factor in development of cervical neoplasia [32]. Women with untreated 
chlamydial diseases have increased risk of HIV infection [33]. Additionally, HIV-infected 
women with reduced CD4+ T cell counts, have increased risk for developing C. trachomatis 
pelvic inflammatory disease (PID) [34•]. Forty six % of men and women infected with Neisseria 
gonorrhoeae also have co-infection with C. trachomatis [29].  
Nineteen serovars based on MOMP seroreactivity predict chlamydial disease biovars: A-C 
(endemic trachoma), D-K (genital diseases) and L1-L3 (lymphogranuloma venereum). C. 
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trachomatis genital serovars infect superficial mucosal epithelia of the urethra in men or 
endocervix in women, initiating disease. In women, C. trachomatis cervical infections are mostly 
asymptomatic and can either resolve spontaneously or progress for weeks to months, causing 
complications [33]. Approximately 25% of women with chlamydial cervicitis have concomitant 
urethritis [33]. Cervical infection can ascend into the endometrium and fallopian tubes and 
develop into chronic infection and PID. PID is characterized by infection and inflammation of 
the upper genital tract frequently involving the endometrium, fallopian tubes, and pelvic 
peritoneum (endometritis, salpingitis or tubo-ovarian abscess and peritonitis). PID is caused by 
common sexually transmitted infections, such as Neisseria gonorrhoeae, Mycoplasma 
genitalium, C. trachomatis (in 30% of clinical cases), and by anaerobic vaginal microbes causing 
bacterial vaginosis [35]. Presumptive diagnosis of PID is made clinically (women of 
reproductive age with pelvic or abdominal pain), while definitive diagnosis is made by 
laparoscopy [35]. If untreated, 8-10% of C. trachomatis infected women develop PID [35]. 
Tubal damage is mediated by innate immune responses and adaptive T-cell responses. Long-
term sequelae of PID include tubal infertility, ectopic pregnancy, and chronic pelvic pain caused 
by tubal damage and scarring from inflammation. The duration of an infection or repeated 
infections affect the pathogenesis of PID, but the relative importance if each has not been 
elucidated. Repeated C. trachomatis infections are common, indicating limited natural immunity. 
Women with active infection can transmit C. trachomatis to their infant during delivery, leading 
to conjunctivitis and pneumonia in the newborn. C. trachomatis infection in pregnant women has 
been also linked to chorioamnionitis, placentitis, premature rupture of membranes, and preterm 
birth [36], however, existing evidence is weak [32]. In men, C. trachomatis causes non-
gonococcal urethritis, epididymitis, prostatitis, and proctitis [37]. Urethritis is the most frequent 
STD syndrome in men and C. trachomatis is the causative agent in 15-40% of cases. The more 
invasive strains causing lymphogranuloma venereum (LGV) are named L1, L2, L2a and L3. 
LGV serovars infect and replicate within macrophages, spread systematically through lymph 
nodes, and cause necrosis and abscesses in inguinal and femoral lymph nodes. LGV proctitis can 
vary from clinically silent to severe. Traditionally, LGV is found most often in Africa, India, 
Southeast Asia, and the Caribbean and almost exclusively in men who have sex with men 
(MSM). Since 2004, increasing incidence has been found in North America, Europe, and 
Australia and occurs mostly in MSM with proctitis [29].  
C. trachomatis infection of the female genital tract is recognized by toll like receptor (TLR)-2 
and TLR-4 and nucleotide-binding oligomerization domain (NOD)1 leading to induction of 
interferon (IFN) gamma. Cell mediated immunity is important in clearance of C. trachomatis 
infection. However, the immune response against C. trachomatis infection does not provide long 
lasting protection and may contribute to pathology. Th1 T helper cell response helps resolve the 
infection, but also leads to secretion of pro-inflammatory factors such as TNF alpha, IL-1alpha 
and IL-6. Induction of IL-10 might down regulate the chlamydial-specific T-cell responses, 
leading to chronic inflammation and tissue damage in persistent infections [38]. Matrix 
metalloproteinase 9 (MMP9) expression by fallopian tube cells infected with C. trachomatis is 
associated with scarring [34•]. Clearance of C. trachomatis infection might be delayed by 
pathogen immune evasion strategies such as enhanced survival inside and outside host cells, 
reduced inflammatory and adaptive immune responses and ability to persist within host cells as 
AB [39]. Adding complexity, sex hormones modulate female genital tract immune responses 
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 7 
[40,41]. Women are more susceptible to chlamydial infection under the influence of estradiol, 
and estradiol enhances disease sequelae [40]. T cell driven INF gamma and Th17 responses are 
critical for clearing infection and play a role in protection from disease [38,42]. Initiation of 
autoimmunity by molecular mimicry has been suggested in the pathogenesis of PID [43]. The 
most important factor in molecular mimicry might be chlamydial heat shock protein 60 (Hsp60). 
Chlamydial Hsp60 is considered the key antigen in immunopathogenesis of tubal infertility, 
stimulating humoral and cell mediated immune responses in women with PID/tubal infertility 
[43]. Increased antibody response to chlamydial Hsp60 in women is strongly associated with 
PID, ectopic pregnancy, and tubal infertility [44].  
Variability in the MOMP gene (ompA) is unrelated to disease severity and MOMP serovars fail 
to correlate with virulence [45]. However, recent data indicate that variation in the pmp genes 
may contribute to disease severity [22•]. Pmps B, D, and H are strongly immunogenic and elicit 
pro-inflammatory cytokine responses [45]. Genital, but not ocular, strains of C. trachomatis 
possess functional tryptophan synthase (trpBA) to convert indole, secreted by local vaginal flora, 
into tryptophan. A perturbed vaginal microbiome (bacterial vaginosis) might provide a source of 
indole, enabling genital C. trachomatis serovars to circumvent tryptophan limiting 
bacteriostatic/bactericidal effects of IFN gamma [46] and establish persistent infection [4]. 
Persistence versus clearance is likely driven by IFN gamma responses. High levels of IFN 
gamma eradicate chlamydiae, but low levels result in the persistent state [42]. Inflammation of 
infected tissues promotes local oxygen consumption, resulting in hypoxia [47]. A recent study 
indicates hypoxia reactivates IFN gamma induced persistent C. trachomatis, causing increased 
bacterial growth and progeny, while dampening the host inflammatory response [48]. 
The C. trachomatis genome is highly conserved and diversity seems to have evolved through 
genetic recombination [49] and might result in hypervirulent strains [22•]. Deletion events also 
occur and have been described in the cryptic plasmid of C. trachomatis. Chlamydial plasmids are 
present in C. trachomatis but are non-conjugative and nonintegrative; they do not encode 
antibiotic resistance nor show signs of genetic flexibility. Therefore, they are targeted for NAAT 
diagnosis of C. trachomatis infection [50]. However, emergence of the new Swedish variant 
(nvCT), a mutated strain from serovar E strains carrying a 377 base pair deletion within its 
plasmid, was reported in 2006. Several commercial NAATs targeted this region, leading to 
diagnostic failure [51]. Retrospective studies suggest nvCT in the Swedish population arose after 
2000, perhaps by importation of the variant or by spontaneous mutation [49]. Genetic 
predisposition and host immune response are also important in pathogenesis of long term 
complications of genital C. trachomatis infection [32]. Specific HLA DQ alleles and 
polymorphisms in the promoter of IL-10 and TNF alpha are associated with high risk of tubal 
infertility [22•], whereas polymorphisms in TLR-2 are associated with protection against tubal 
disease following C. trachomatis infection [36]. 
Diagnosis of C. trachomatis infection is recommended by NAAT from urine, vaginal, or 
endocervical swabs. NAAT from non-genital samples, such as rectal swabs, is performed but not 
FDA-approved and is essential to diagnose LGV proctitis [33]. Self-collected vaginal or urine 
swabs are most commonly used in screening programs. The CDC recommends annual screening 
for C. trachomatis in sexually active women aged 25 years and younger [31]. Upon diagnosis, 
primary uncomplicated urogenital infections can be effectively treated with antibiotics. The CDC 
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 8 
recommends either single-dose azithromycin or a 7-day course of doxycycline in adolescent and 
adult men and women, and amoxicillin in pregnant women [52]. Early treatment of C. 
trachomatis infected individuals shortens infection duration and prevents sexual transmission 
and complications including PID, while treatment of pregnant women prevents transmission to 
the infant during delivery [52]. However, most chlamydial infections are asymptomatic and 
undiagnosed/untreated. Treatment failure occurs [42], perhaps due to re-infection, persistent 
infection or, less likely, acquired antibiotic resistance. Recurrent C. trachomatis infections result 
from re-infection from an untreated partner or infection from a new partner [52]. Moreover, 
prevalence of anorectal chlamydia is high; almost all women with anorectal chlamydia had 
concurrent urogenital chlamydia [53]. This finding has implications for the diagnosis of C. 
trachomatis infections (both sites should be tested) and for the therapy (anorectal chlamydial 
infections are more difficult to treat). Moreover, anorectal infection might lead to recurrent 
vaginal infection by autoinoculation [54]. Treatment of LGV infection requires prolonged 
therapy (21 days) and the CDC recommends doxycycline [52].  
Screening programs aim to identify and treat asymptomatic cases of cervicitis before C. 
trachomatis infection can progress to PID [35]. Trials indicate Chlamydia screening and 
treatment reduces risk of PID among young women [55]. Screening has contributed to the 
decline of PID; however, the magnitude of benefit might have been overestimated in initial trials. 
Asymptomatic chlamydial infections may have been present for months when detected by 
screening, and thus might have already progressed to chronic inflammation in the upper genital 
tract. The role of chlamydial screening in reducing complications has not been confirmed and 
benefit on an individual level is difficult to assess [55]. Future focus should include screening 
young, sexually active women; determining optimal frequency of screening and benefit of 
screening for repeat infections; and, of major importance, treatment of partners of infected 
women [56]. In addition to preventing adverse sequelae of C. trachomatis infection, reducing the 
incidence of new infections through interruption of transmission might be equally important 
[55]. Despite screening and control programs, reported C. trachomatis cases have not exhibited 
sustained declines. This may be explained by the arrested immunity hypothesis: early treatment 
interrupts acquisition of protective immunity, increasing risk of reinfection [57,58]. A recent 
clinical study provides data supporting this concept, indicating spontaneous resolution of 
chlamydial infection, in absence of antibiotic treatment, may reduce risk of subsequent 
reinfection [59]. Development of a safe and effective C. trachomatis vaccine to prevent 
acquisition and transmission of infection, and prevent development of inflammatory sequelae, 
remains the ultimate goal [42,57]. 
 
 
Chlamydia pneumoniae: respiratory infections, coronary artery disease and atherosclerosis 
 
Chlamydia (C.) pneumoniae causes a wide range of acute and chronic respiratory diseases and 
has been associated with atherosclerosis and cardiovascular disease. The chlamydial organism 
Taiwan acute respiratory agent (TWAR) was classified in 1989 as a new species, C. pneumoniae 
[60]. Human C. pneumoniae strains are highly conserved, in contrast to animal strains which are 
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thought to be ancestral [61]. Although C. pneumoniae is an acute human respiratory pathogen, 
much research has focused on its role in chronic infections. C. pneumoniae is essentially 
ubiquitous, with seropositivity of 50% by the age of 20 years and 70-80% by 60-70 years [62]. 
Most acute infections are asymptomatic or manifest as mild, self-limiting upper respiratory tract 
infections. However, progression to severe upper respiratory tract infections (pharyngitis, 
sinusitis, and otitis) and lower respiratory tract infections such as acute and chronic bronchitis, 
asthma, and pneumonia occurs [63,64]. C. pneumoniae is believed to account for around 10% of 
community-acquired pneumonia (CAP), 5% of pharyngitis, bronchitis and sinusitis [65], and can 
exacerbate chronic bronchitis and asthma.  
 
CAP can be of bacterial and/or viral etiology [66]. Bacterial CAP is usually caused by 
Streptococcus pneumoniae; other common pathogens involved are Staphylococcus aureus, 
Haemophilus influenzae, Enterobacteriaceae, Legionella pneumoniae, Mycoplasma pneumoniae, 
and Chlamydia pneumoniae. A prospective study of German CAP patients identified C. 
pneumoniae in respiratory samples in only 0.9% cases by PCR [67]. In contrast, another study 
identified C. pneumoniae as the second most common pathogen in CAP patients in North and 
South America, with a global incidence of 7% [68]. The incubation period is around 21 days, 
with transmission by respiratory secretions [64].  
 
Clinically, the causative pathogen of CAP is often unidentified, and commercially available 
FDA-approved NAATs for C. pneumoniae are not available [69]. Microimmunofluorescence 
testing (MIF) is the reference standard for serodiagnosis of C. pneumoniae infection. However, 
MIF cannot differentiate acute versus chronic infection nor discriminate between past and 
persistent infections [70].  Common treatment for CAP is empiric antibiotic therapy with a beta-
lactam in combination with macrolides, respiratory fluoroquinolones or tetracyclines [71]. 
Specific treatment of C. pneumoniae induced acute respiratory infection is successful with 
macrolides, tetracyclines, or respiratory fluoroquinolones [66]. However, the benefit of treatment 
is difficult to assess as the majority of the studies have relied on serology for the diagnosis of C. 
pneumoniae induced respiratory infections [52]. Serology often does not correlate with pathogen 
detection by culture or PCR, especially in children, where more than 70% of culture positive 
children with CAP are seronegative [69].  
 
In respiratory C. pneumoniae infections, the innate immune response is likely mediated by Toll-
like receptor (TLR) 2 and TLR4 induced early cytokine and chemokine production via MyD88 
[72•]. NOD and NOD-like receptors might play a role in prolonged activation of host cells. 
Bronchial epithelial cells are the first line of defense during C. pneumoniae infection, but after 
initial infection the pathogen resides in macrophages and neutrophils. C. pneumoniae infection is 
also associated with asthma and, in particular, asthma exacerbation. C. pneumoniae-specific IgE 
is prevalent in asthma patients, and occurrence of these species-specific antibodies is associated 
with disease severity [73]. The most widely accepted association of C. pneumoniae respiratory 
infection with exacerbation of asthma is documented by multiple epidemiologic and clinical 
studies, some of which investigated whether antibiotic treatment in asthma patients improves 
outcome. However, macrolides, quinolones, ketolides and tetracyclines all have 
immunomodulatory activity independent of their antimicrobial activity, which might influence 
outcome. To date, the benefit of antibiotics in asthma patients without evidence of acute 
infection remains controversial [52].  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 10 
 
Atherosclerosis, the leading cause of death in industrialized countries, causes coronary artery 
disease (CAD) and cerebrovascular disease and is defined as a chronic inflammatory disease of 
multifactorial etiology. It is characterized by endothelial cell injury, proliferation of vascular 
cells and ensuing accumulation of inflammatory cells which secrete pro-inflammatory molecules 
such as IL-1, IL-6 and TNF alpha, inciting an oxidative stress response [74]. Besides well-known 
cardiovascular risk factors (hypertension, hyperlipidemia, diabetes, smoking and obesity), 
several infectious agents such as cytomegalovirus, influenza A virus, hepatitis C virus, HIV, 
Helicobacter pylori, periodontal pathogens, and C. pneumoniae have been implicated in 
pathogenesis of atherosclerosis [75,76]. However, C. pneumoniae is the only one of these 
pathogens that has been repeatedly detected in atherosclerotic lesions and cultivated from 
atheromatous plaques. Association of C. pneumoniae with atherosclerosis and coronary heart 
disease is based on both seroepidemiological studies and direct detection of the microorganism 
in the atheroma by PCR, immunohistochemistry, in situ hybridization, electron microscopy and 
culture. Animal models have also demonstrated that progression of atherosclerotic lesions is 
accelerated by C. pneumoniae infection [75,77•]. In human patients, after initial respiratory 
infection, the pathogen can disseminate from the lungs through peripheral blood mononuclear 
cells, replicating and persisting in vascular tissue cells – further suggesting a role in the 
pathobiology of atherosclerosis.  
 
Chlamydial lipopolysaccharide (LPS) and chlamydial Hsp60 are important C. pneumoniae 
virulence factors. Molecular mimicry between bacterial and self antigens such as heat shock 
proteins might contribute to pathogenesis [75]. In response to infection with C. pneumoniae, 
acute phase proteins enhance progression and destabilization of atherosclerotic plaques [76]. C. 
pneumoniae can induce proliferation of vascular smooth muscle cells (VSMCs) and stimulate 
production of numerous pro-inflammatory mediators and adhesion molecules in VSMCs and 
endothelial cells [76,78,79]. C. pneumoniae infection can also induce reactive oxygen species 
(ROS) in macrophages, platelets, endothelial cells and VSMCs, contributing to atherosclerotic 
lesion development [74]. Progression of atherosclerotic lesions is viewed as host response to 
noxious stimuli, and C. pneumoniae infection might represent one among many such possible 
stimuli. Furthermore, it is unclear if C. pneumoniae is involved in induction of atherosclerotic 
lesions or if it is a mere colonizer and bystander of already injured vascular tissue. Nevertheless, 
C. pneumoniae may be the only pathogen for which both a direct and an indirect contribution to 
atherosclerosis have been demonstrated. In evidence of this, antigen and/or DNA/RNA of C. 
pneumoniae has been detected in human plaques but never found in normal vascular tissue, 
viable organisms have been isolated from plaques, C. pneumoniae-related increased pro-
inflammatory response has been shown, and atherosclerotic lesions in mouse and rabbit animal 
models were accelerated by C. pneumoniae infection.  
 
The association between infectious agents, in particular C. pneumoniae, and CAD led to clinical 
trials assessing antibiotic treatment [75]. Cumulatively, these trials demonstrated anti-chlamydial 
antibiotic treatment was ineffective in coronary heart disease patients, leading to the assumption 
that C. pneumoniae is not involved in the pathogenesis of atherosclerosis [77•]. However, several 
factors were not considered during these trials: treatment was given to patients suffering “end 
stage disease” with advanced atherosclerotic lesions unlikely to be influenced by antibiotic 
treatment; other related pathogens such as bacteria and viruses involved in the atherosclerotic 
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process were not considered; a single antibiotic was used although a combination might have 
been more effective; and, finally, potential persistent forms within atherosclerotic lesions was not 
considered, though it is known from in vitro studies that persistent chlamydial organisms are 
refractory to antibiotic treatment [77•].  
 
 
Chlamydia-induced arthritis 
The spondyloarthritides (SpA) are rheumatoid factor-negative, HLA-B27-associated arthritic 
diseases characterized by four clinical features: i) inflammatory back pain, ii) asymmetric 
peripheral oligoarthritis, usually of the lower limbs, iii) enthesitis, and iv) extra-articular 
inflammatory symptoms, most commonly uveitis [80]. Five subgroups comprise the SpA, 
including ankylosing spondylitis, inflammatory bowel disease-associated SpA, psoriasis-
associated SpA, reactive arthritis and undifferentiated SpA. Reactive arthritis (ReA) has similar 
clinical presentation to other SpA, but specifically develops subsequent to bacterial enteric, 
urogenital, or, less frequently, respiratory infection, typically within 1 to 3 weeks after the 
triggering infection [81]. In enteric-associated ReA Yersinia, Salmonella, Shigella, and 
Campylobacter predominate, while C. trachomatis is the most common in urogenital-associated 
ReA, and the respiratory pathogen C. pneumoniae is also associated with the disease [82•]. C. 
trachomatis genital infections and C. pneumoniae infections account for about 50% and 12% of 
all ReA, respectively [82•,83]. Septic arthritis, also initiated by infection, but not in the SpA 
group, is associated with actively infected synovium/synovial fluids, in contrast to ReA in which 
synovial cultures are typically negative [81]. However, in Chlamydia-induced ReA 
bacteria/bacterial products can be found in affected joint(s) [83]. This indicates the traditional 
description of ReA, having affected but non-infected joints, is inaccurate in the case of 
Chlamydia-induced ReA. The disease instead shares characteristics of both ReA, defined by 
autoimmune reaction-induced symptoms, and septic arthritis, defined by infection-induced 
inflammation [84•]. Here we use the term Chlamydia-induced arthritis (CiA) in reference to ReA 
induced by C. trachomatis and/or C. pneumoniae.    
 
In CiA, and other ReA, all associated clinical features are frequently not present and the clinical 
presentations can be quite variable. College of Rheumatology general guidelines can be used as 
diagnostic criteria for ReA, indicating probable or definitive ReA depending on satisfaction of 
major and/or minor criteria based on clinical presentation, preceding symptomatic enteric or 
urogenital infection, and laboratory proof or evidence of triggering or persistent synovial 
infection [81]. Currently, however, no national or international guidelines exist for diagnosis or 
classification of ReA, and incidence and prevalence of ReA and CiA remain unclear. The Office 
of Rare Diseases Research of the National Institutes of Health categorizes ReA as rare, affecting 
less than 200,000 individuals in the United States (USA) [85]. Notably, with up to 80% of 
Chlamydia infections, and up to 90% of C. pneumoniae infections specifically, expected to be 
asymptomatic [84•,85], it is likely ReA and CiA are underdiagnosed.  High incidence of genital 
Chlamydia infections, estimated to be over 3 million annually in the USA and up to 115 million 
annually worldwide, and reports that approximately 4% of those with acute genital chlamydial 
infection will develop ReA/CiA, have prompted some to calculate that at least 120,000 new 
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cases of C. trachomatis-induced ReA are likely to occur annually in the USA [82•].  The USA 
and worldwide prevalence of CiA, if such calculations are accurate, might not be considered 
rare.  Additionally, three recent case reports [86–88] of well-documented CiA following C. 
trachomatis LGV L2 proctitis, all in HIV-positive MSM, indicate that the ongoing increased 
incidence of C. trachomatis LGV L2 proctitis in Europe, Australia and North America [29] may 
be expected to correlate with increased CiA incidence. This has led some to suggest that 
screening for C. trachomatis LGV L2 in all HIV-positive MSM presenting with acute arthritis 
may be beneficial even in the absence of proctitis, because infection can be asymptomatic [86]. 
ReA is usually self-limiting, with spontaneous symptom resolution within 6 months in 
approximately 50% to 70% of cases; however, 30% to 50% of patients progress to chronic 
infection, often with remitting-relapsing disease course [82•]. Significant pain, loss of activity, 
and economic costs are reported for ReA and are similar to other arthritic diseases, such as 
members of the SpA group and rheumatoid arthritis [89].   
 
Host and bacterial factors contributing to CiA pathogenesis have not been clearly determined. 
HLA-B27 allele positivity has traditionally been associated with CiA/ReA and the other SpA 
groups. Early studies reported that up to 80% of ReA cases were HLA-B27 positive, while more 
recent studies indicate that 30% to 50% of all ReA cases are associated with the allele. Thus, 
HLA-B27 is currently thought to more accurately represent a risk factor for progression to 
chronic disease and/or increased disease severity in ReA, rather than a risk factor for ReA 
susceptibility [85]. In ReA other than CiA, the triggering organism is absent from affected joints 
and pathogenesis is thought to occur largely based on autoimmune factors initiated by distal or 
resolved infection. However, viable C. trachomatis and/or C. pneumoniae have been 
demonstrated in affected joints by both electron microscopy and PCR [85]. This suggests that, 
although host autoimmunity might contribute to pathogenicity, the immune response to an 
ongoing joint infection may also affect disease pathogenesis.  
 
Viable Chlamydia exists in the joint, apparently as a long-term infection, in a state usually 
referred to as persistence [85]. Persistent organisms are metabolically active, non-cultivable and 
exhibit altered patterns of gene expression. Persistence can be induced in vitro and in animal 
models by a variety of conditions including amino acid or iron deprivation, antibiotic or IFN 
gamma exposure, co-infection with viruses or parasites, and heat shock [3•]. Chlamydia 
disseminates to joints from the initial site of infection via monocytes, and once in the joints, the 
chlamydiae infect macrophages and/or macrophage-like and fibroblast-like cells of the synovium 
[82•,84•,90]. Interestingly, the persistent state appears to occur, at least in part, due to Chlamydia 
infection of monocytes and macrophages, which do not support normal, productive infection 
[82•]. Cells of the synovium, along with T cells present in infected joint(s), mount a protective 
immune response to Chlamydia involving production of cytokines such as IFN gamma, TNF 
alpha, and various interleukins - a response that is important for clearance of Chlamydia 
infection, but also involved in inflammatory joint damage via cartilage and bone deterioration 
[90]. Chlamydial Hsp60 proteins play a major role in the host inflammatory response.  In vitro, 
chlamydial Hsp60 genes show altered expression during persistent infection, and synovial 
samples from patients with chronic CiA reflect this [82•]. Diagnosis of continued bacterial 
presence indicates pathogen survival, and thus implies that the immune response is ineffective in 
clearing the infection. However, this immune response also causes inflammatory joint damage. It 
has been postulated that damage results from skewing of the T helper cell response from a Th1 
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dominant response to a Th2 dominant response, a process in which the persistent state of 
Chlamydia itself might play a role [84•]. A recent study showed bacterial DNA and 
inflammatory cytokine/chemokine and Hsp60 transcripts can be found in the joint during the 
remitting phase of chronic CiA, suggesting damaging inflammation is ongoing even during 
symptom remission [91]. 
 
Host genetic variability, outside of HLA-B27 phenotype, is likely important in initial and 
continued immune response to infection, especially considering the low proportion of cases of 
acute Chlamydia infection resulting in CiA. Initially high levels of IFN gamma and TNF alpha in 
the synovium are associated with resistance to experimentally induced CiA [84•]; and it has 
subsequently been suggested that host-determined low initial cytokine levels at the time of acute 
Chlamydia infection might potentiate chronic disease progression, perhaps dependent to some 
degree on the persistent Chlamydia state [92]. Indirect evidence supports the concept that the 
Chlamydia persistent state may contribute to pathogenesis of CiA. A study evaluating 36 patients 
with confirmed CiA, all with synovial samples positive for C. trachomatis by PCR, exclusively 
identified ocular, not genital, strains of C. trachomatis [93]. This lead the authors to surmise C. 
trachomatis ocular strains might have a particular capacity for dissemination from the genital 
tract, and the small percentage of C. trachomatis cases progressing to CiA might reflect the small 
percentage of cases of in which ocular strains are found in genital infection [93]. C. trachomatis 
ocular strains and C. pneumoniae human strains, the chlamydiae commonly demonstrated to be 
involved in CiA, are unable to synthesize tryptophan and thus have increased sensitivity to the 
host IFN gamma response and subsequent tryptophan deprivation, a characteristic that might 
facilitate persistence as a means of initiating and maintaining chronic infection [94,95]. 
 
Treatment of CiA is not well studied, and therapy relies largely on managing the disease and 
treating symptoms. Non-steroidal anti-inflammatory drugs, corticosteroids and the disease 
modifying anti-rheumatic drug sulfasalazine have shown some efficacy for certain stages or 
severity of CiA [82•]. A meta-analysis of 12 antibiotic treatment studies showed long term 
antibiotic treatment does not significantly improve disease outcome [96], a finding that may 
support the concept that continued infection in CiA correlates with, but does not cause ReA. 
However, a single trial examining combined 6 month use of a macrolide or tetracycline with 
rifampin, demonstrated that chronic CiA patients showed significant improvement and increased 
negative Chlamydia PCR diagnosis with combination antibiotic therapy compared to placebo, a 
finding the authors suggested might reflect that persistent chlamydiae are refractory to standard 
antibiotic treatment [85]. Anti-TNF alpha treatment, commonly used for rheumatoid arthritis, has 
shown efficacy for CiA [92]. However, given the importance of TNF alpha and other 
inflammatory cytokines in control of Chlamydia infection, more studies are needed to evaluate 
this therapy in CiA. In fact, many confounding factors encompass ReA and CiA, complicating 
pursuit of effective therapy. The relationship between continued joint infection, subsequent to 
initial Chlamydia infection, and CiA disease inception or progression has not yet been proven a 
causal relationship, and the importance of eradicating underlying chlamydial infection for 
resolution of CiA is thus unknown. The basic biology underlying the persistent state of 
Chlamydia in joint infection is also poorly understood, and the in vivo diagnosis, as well as the 
consequence of persistent infection, remains to be elucidated [20].   
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Conclusions 
 
Chronic chlamydial infections are implicated in trachoma, sexually transmitted genital diseases, 
atherosclerosis and arthritis. These infections are characterized by prolonged and chronic 
inflammation, scarring and fibrosis mediated by continuous stimulation of the host immune 
response. Multiple host and chlamydial factors contribute significantly to specific chlamydial 
chronic diseases. However, several characteristics of chlamydiae and chlamydial infection are 
especially relevant to the propensity of this organism to establish chronic disease in general: i) 
infection of multiple cell types and dissemination within the host, ii) the intracellular niche of the 
chlamydiae, iii) immune evasion allowing enhanced chlamydial survival by modulation of 
apoptosis, pathogen detection, and inflammatory and adaptive immune responses in the host 
[39,97], and iv) frequent asymptomatic infection which can make detecting chlamydiae difficult.  
 
Additionally, recent findings have broad implications for diagnosis and treatment of chlamydial 
infections. First, although the importance of chlamydial persistence in vivo remains unclear, 
persistent growth forms (AB) can be found in the human endocervix (by electron microscopy) 
where the local microenvironment at infection is similar to the in vitro model of IFN gamma 
persistence induction [98]. If the chlamydial persistent state is, in fact, present in vivo, both 
detection by culture (persistent chlamydiae are by definition non-cultivable) and treatment of 
chlamydial infection may be impacted. Persistent chlamydiae are resistant to killing by 
antibiotics in vitro; and a model of amoxicillin induced C. muridarum persistence in mice 
indicates persistent chlamydiae are resistant to killing by azithromycin in vivo as well [99]. 
Furthermore, clinically relevant concentrations of commonly used penicillins induce C. 
trachomatis persistence in vitro [100]. Second, tetracycline resistance in chlamydiae may be 
possible.  Evidence of antibiotic resistance in human pathogenic chlamydiae is lacking, based on 
the observation that suspected tetracycline resistant strains lost the resistant phenotype during 
culture and failed to exhibit genomic evidence of resistance [101]. However, isolation of 
tetracycline resistant C. suis from pigs demonstrates an adaptive ability of chlamydiae to acquire 
antibiotic resistance under selective pressure [102], with implications for continued use of 
antibiotic treatment of chlamydial disease.  Third, and finally, chlamydiae have long been known 
to colonize the gastrointestinal (GI) tracts of animal hosts, including poultry and sheep, without 
causing disease [54]. And although humans can become rectally infected with C. trachomatis, 
long-term intestinal infection in humans has not yet been confirmed [54]. Mouse model studies 
show chlamydiae infecting the GI tract can persist for up to 100 days with no pathology, and 
azithromycin treatment sufficient to cure genital infection did not similarly cure GI tract 
infection, despite drug levels in both anatomical sites [103•]. Thus, intestinal carriage of 
chlamydiae may not only allow auto- or re-inoculation of the genital tract, but may represent 
commensal association with the human host, providing a degree of incidental antibiotic 
resistance [54]. 
These findings indicate that future research in the areas of chlamydial persistence, mechanisms 
of protective immunity and immunopathology, and vaccine development is a priority. Given 
difficulties surrounding diagnosis and antibiotic treatment of chlamydial disease, development of 
an effective Chlamydia vaccine appears particularly advantageous in the context of chronic 
disease. Recent data from a non-human primate animal model demonstrated the efficacy of 
plasmid-deficient chlamydial strains as live attenuated vaccines against genital and ocular 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 15 
chlamydial infections [50], and vaccine development is underway [34•,42]. Continued study of 
the intricate biology of the chlamydiae will facilitate advances in prevention, diagnosis and 
treatment of chronic chlamydial disease. 
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